PPAR gamma 2 Prevents Lipotoxicity by Controlling Adipose Tissue Expandability and Peripheral Lipid Metabolism
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator activated receptor gamma 2 (PPARg2) is the nutritionally regulated isoform of PPARg. Ablation of PPARg2 in the ob/ob background, PPARg2(-/-) Lep(ob)/Lep(ob) (POKO mouse), resulted in decreased fat mass, severe insulin resistance, beta-cell failure, and dyslipidaemia. Our results indicate that the PPARg2 isoform plays an important role, mediating adipose tissue expansion in response to positive energy balance. Lipidomic analyses suggest that PPARg2 plays an important antilipotoxic role when induced ectopically in liver and muscle by facilitating deposition of fat as relatively harmless triacylglycerol species and thus preventing accumulation of reactive lipid species. Our data also indicate that PPARg2 may be required for the beta-cell hypertrophic adaptive response to insulin resistance. In summary, the PPARg2 isoform prevents lipotoxicity by (a) promoting adipose tissue expansion, (b) increasing the lipid-buffering capacity of peripheral organs, and (c) facilitating the adaptive proliferative response of beta-cells to insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760
Inflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
Kim, H. J., Park, S. Y., Choi, Y. J., Han, S. J., Lee, K. W., & Kim, D. J. (2013) · Hormone Research in Paediatrics · doi:10.1159/000348848 · Cited by 3,048
Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0039 · Cited by 2,232
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Inflammation: the link between insulin resistance, obesity and diabetes
Dandona, P. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.013 · Cited by 2,170 · cited 1×
“Cytokines produced by these adipocytes or macrophages may directly antagonise insulin signalling [3,4].”
BackgroundPPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro
Rosen, E. D., Sarraf, P., Troy, A. E., Bradwin, G., Moore, K., Milstone, D. S., Spiegelman, B. M., & Mortensen, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80211-7 · Cited by 2,079
PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development
Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R., Koder, A., & Evans, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80209-9 · Cited by 1,956
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 1×
“Of interest, Ppargc1a and other gluconeogenic genes were induced in the liver of POKO mice compared to that of ob/ob mice, suggesting a potential mechanism contributing to marked hyperglycaemia in POKO mice [53,54].”
Background
Cited by
Pluskal, T., Castillo, S., Villar-Briones, A., & Orešič, M. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-395 · Cited by 3,845
Self-citation(1998) · PubMed · Cited by 2,737
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
NF-κB, Inflammation, and Metabolic Disease
Baker, R. G., Hayden, M. S., & Ghosh, S. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2010.12.008 · Cited by 1,952
Grygiel-Górniak, B. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-17 · Cited by 1,079
Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome — An allostatic perspective
Virtue, S., & Vidal-Puig, A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.12.006 · Cited by 1,013
Self-citationDunn, W. B., Broadhurst, D. I., Atherton, H. J., Goodacre, R., & Griffin, J. L. (2011) · Chem. Soc. Rev. · doi:10.1039/b906712b · Cited by 860
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Janani, C., & Ranjitha Kumari, B. D. (2015) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2014.09.015 · Cited by 735
Comprehensive analysis of lipids in biological systems by liquid chromatography-mass spectrometry
Cajka, T., & Fiehn, O. (2014) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2014.04.017 · Cited by 650
Characterizing the profile of obese patients who are metabolically healthy
Primeau, V, Coderre, L., Karelis, A. D., Brochu, M., Lavoie, M.-E., Messier, V, Sladek, R., & Rabasa-Lhoret, R. (2011) · International Journal of Obesity · doi:10.1038/ijo.2010.216 · Cited by 637
Adipogenesis and WNT signalling
Christodoulides, C., Lagathu, C., Sethi, J. K., & Vidal-Puig, A. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.09.002 · Cited by 598
Self-citationNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy-Wenzig, E.-M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 594
EPIC-InterAct Consortium, Lotta, L. A., Cambridge FPLD1 Consortium, Gulati, P., Day, F. R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K. J., Eicher, J. D., et al. (2017) · Nature Genetics · doi:10.1038/ng.3714 · Cited by 585
Sethi, J. K., & Vidal-Puig, A. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700005-jlr200 · Cited by 563
Self-citationObesity and related consequences to ageing
Jura, M., & Kozak, L. P. (2016) · AGE · doi:10.1007/s11357-016-9884-3 · Cited by 473
JNK1 and IKKβ: molecular links between obesity and metabolic dysfunction
Solinas, G., & Karin, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-151340 · Cited by 347
It's Not How Fat You Are, It's What You Do with It That Counts
Virtue, S., & Vidal-Puig, A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060237 · Cited by 312
Self-citationKeiran, N., Ceperuelo-Mallafré, V., Calvo, E., Hernández-Alvarez, M. I., Ejarque, M., Núñez-Roa, C., Horrillo, D., Maymó-Masip, E., Rodríguez, M. M., Fradera, R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0372-7 · Cited by 290
PPARγ activation in adipocytes is sufficient for systemic insulin sensitization
Sugii, S., Olson, P., Sears, D. D., Saberi, M., Atkins, A. R., Barish, G. D., Hong, S.-H., Castro, G. L., Yin, Y.-Q., Nelson, M. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912487106 · Cited by 255
PPARs and lipid ligands in inflammation and metabolism
Harmon, G. S., Lam, M. T., & Glass, C. K. (2011) · Chemical Reviews · doi:10.1021/cr2001355 · Cited by 216
Cherian, S., Lopaschuk, G. D., & Carvalho, E. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00061.2012 · Cited by 185
“Animal studies have also provided evidence that activation of transcriptional pathways that regulate the expression of fatty acid oxidation enzymes might induce lipotoxicity and cardiac dysfunction (37, 100, 129).”
BackgroundXu, J., Kulkarni, S. R., Donepudi, A. C., More, V. R., & Slitt, A. L. (2012) · Diabetes · doi:10.2337/db11-1716 · Cited by 183
“The increased adipogenesis caused by TZD can be interrupted by disruption of PPARg gene expression (16).”
BackgroundMethodLa Paglia, L., Listì, A., Caruso, S., Amodeo, V., Passiglia, F., Bazan, V., & Fanale, D. (2017) · PPAR Research · doi:10.1155/2017/8187235 · Cited by 174
“Similar to PPAR"/# isoform, it regulates the activity of proteins like LPL [139, 140].”
Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2
Lee, Y. K., Park, J. E., Lee, M., & Hardwick, J. P. (2018) · Liver Research · doi:10.1016/j.livres.2018.12.001 · Cited by 173
Garbow, J. R., Doherty, J. M., Schugar, R. C., Travers, S., Weber, M. L., Wentz, A. E., Ezenwajiaku, N., Cotter, D. G., Brunt, E. M., & Crawford, P. A. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00539.2010 · Cited by 170
“The adipocyte form, PPAR 2, is induced in liver in the setting of traditional WD-induced hepatic steatosis, and, whereas selective elimination of PPAR 2 by gene targeting reduces hepatic steatosis, its loss also worsens lipotoxicity and insulin resistance (28, 43, 50, 53, 68).”
BackgroundTan, C. Y., & Vidal-Puig, A. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360935 · Cited by 169
Self-citationVila, I. K., Badin, P.-M., Marques, M.-A., Monbrun, L., Lefort, C., Mir, L., Louche, K., Bourlier, V., Roussel, B., Gui, P., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.062 · Cited by 165
Wang, X.-A., Zhang, R., She, Z.-G., Zhang, X.-F., Jiang, D.-S., Wang, T., Gao, L., Deng, W., Zhang, S.-M., Zhu, L.-H., et al. (2014) · Hepatology · doi:10.1002/hep.26751 · Cited by 159
Phenotypic flexibility as key factor in the human nutrition and health relationship
van Ommen, B., van der Greef, J., Ordovas, J. M., & Daniel, H. (2014) · Genes & Nutrition · doi:10.1007/s12263-014-0423-5 · Cited by 133
Pancreatic β-Cell Proliferation in Obesity
Linnemann, A. K., Baan, M., & Davis, D. B. (2014) · Advances in Nutrition · doi:10.3945/an.113.005488 · Cited by 132
Patsouris, D., Cao, J.-J., Vial, G., Bravard, A., Lefai, E., Durand, A., Durand, C., Chauvin, M.-A., Laugerette, F., Debard, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110653 · Cited by 122
“In consequence, while WAT macrophages may promote early events in the development of diabetes, skeletal muscle macrophages may instead contribute to late stages of evolution of the disease, consistently with the adipo-centric models of diabetes etiology [28–30].”
BackgroundGrasa-López, A., Miliar-García, Á., Quevedo-Corona, L., Paniagua-Castro, N., Escalona-Cardoso, G., Reyes-Maldonado, E., & Jaramillo-Flores, M.-E. (2016) · Marine Drugs · doi:10.3390/md14080148 · Cited by 111
“PPARγ has been proved to promote apoptosis of large hypertrophic mature adipocytes and to stimulate instead the production of small insulin sensitive adipocyte, also playing an important role in insulin sensitivity [40,41].”
BackgroundLeptin resistance is a secondary consequence of the obesity in ciliopathy mutant mice
Berbari, N. F., Pasek, R. C., Malarkey, E. B., Yazdi, S. M. Z., McNair, A. D., Lewis, W. R., Nagy, T. R., Kesterson, R. A., & Yoder, B. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210192110 · Cited by 98
Dankel, S. N., Svärd, J., Matthä, S., Claussnitzer, M., Klöting, N., Glunk, V., Fandalyuk, Z., Grytten, E., Solsvik, M. H., Nielsen, H., et al. (2014) · Obesity · doi:10.1002/oby.20758 · Cited by 95
“We found that COL6A3 mRNA was negatively regulated by PPARc, a key regulator of adipogenesis and modulator of insulin sensitivity (24-26).”
BackgroundInfluentialBiology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
“PPAR 2 systemic deletion Decreased fat mass, severe IR, -cell failure, and dyslipidaemia in leptin-deficient mice [419]”
BackgroundObesity and Pregnancy, the Perfect Metabolic Storm
Corrales, P., Vidal-Puig, A., & Medina-Gómez, G. (2021) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00914-5 · Cited by 51
Self-citationLuo, H., Zhou, Y., Hu, X., Peng, X., Wei, H., Peng, J., & Jiang, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1033594 · Cited by 36
“Therefore, it is easy to understand that the increase of intramuscular adipose tissue could contribute to the maintainance of insulin sensitivity in skeletal muscle.(1,39) n-3 PUFA, especially those from marine oil, i.”
BackgroundThe new therapeutic frontier--nuclear receptors and the liver
Karpen, S. J., & Trauner, M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.002 · Cited by 29
“This concept is exemplified by ablation of the proadipogenic transcription factor PPARc2 (expressed exclusively in WAT) in the ob/ob background (POKO mouse) [32], resulting in decreased fat mass, but severe insulin resistance, b-cell failure, and dyslipidemia.”
BackgroundGuru, B., Tamrakar, A. K., Manjula, S. N., & Prashantha Kumar, B. R. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175322 · Cited by 18
Metadata
- Authors
- Medina-Gomez, G., Gray, S. L., Yetukuri, L., Shimomura, K., Virtue, S., Campbell, M., Curtis, R. K., Jimenez-Linan, M., Blount, M., Yeo, G. S. H., Lopez, M., Seppänen-Laakso, T., Ashcroft, F. M., Orešič, M., & Vidal-Puig, A.
- Venue
- PLoS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-04-27
- Volume
- 3
- Issue
- 4
- Pages
- e64
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- OpenAlex
- W1997304834
- Cited by
- 430
- References
- 60
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.